JIUN-KAE JACK LEE to Proto-Oncogene Proteins
This is a "connection" page, showing publications JIUN-KAE JACK LEE has written about Proto-Oncogene Proteins.
Connection Strength
0.186
-
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res. 2013 Jan 01; 19(1):279-90.
Score: 0.054
-
PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One. 2011; 6(7):e22769.
Score: 0.049
-
bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res. 1995 Jan 15; 55(2):237-41.
Score: 0.016
-
Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. Mol Cancer Ther. 2013 Dec; 12(12):2857-63.
Score: 0.014
-
Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial. J Thorac Oncol. 2013 May; 8(5):658-61.
Score: 0.014
-
PIK3CA mutations in advanced cancers: characteristics and outcomes. Oncotarget. 2012 Dec; 3(12):1566-75.
Score: 0.014
-
High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation. J Thorac Oncol. 2012 May; 7(5):833-40.
Score: 0.013
-
Cotargeting cyclin D1 starts a new chapter in lung cancer prevention and therapy. Cancer Prev Res (Phila). 2011 Jun; 4(6):779-82.
Score: 0.012